Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2446 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Xiaonan Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Glucuronosyltransferase, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, the National Institute of Neurological Disorders and Stroke, NIAMS NIH HHS, US Department of Defense, CDMRP.
Abstract (Originalsprache)
Human genetic variation (polymorphisms) in genes coding proteins involved in the absorption, distribution, metabolism, and elimination (ADME) of drugs can have a strong effect on drug exposure and downstream efficacy and safety outcomes. Vamorolone, a dissociative steroidal anti‐inflammatory drug for treating Duchenne muscular dystrophy (DMD), primarily undergoes oxidation by CYP3A4 and CYP3A5 and glucuronidation by UDP‐glucuronosyltransferases. This work assesses the pharmacokinetics (PKs) of vamorolone and sources of interindividual variability (IIV) in 81 steroid‐naïve boys with DMD aged 4 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
- Department of Neurosciences, University of Padova, Padua, Italy.
- Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
- John Walton Centre for Neuromuscular Disease, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, UK.
- Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
- ReveraGen BioPharma, Rockville, MD, USA.
ORCID-Profile: Xiaonan Li, William J Jusko
Förderung
- National Institutes of Health, the National Institute of Neurological Disorders and Stroke
- NIAMS NIH HHS
- US Department of Defense, CDMRP
- NIH HHS
- NICHD NIH HHS
- National Institute of Child Health and Human Development
- NIGMS NIH HHS
- NINDS NIH HHS
Zitieren
APA
Li, X., Sabbatini, D., Pegoraro, E., Bello, L., Clemens, P., Guglieri, M., van den Anker, J., Damsker, J., McCall, J., Dang, U. J., Hoffman, E. P., & Jusko, W. J. (2024). Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2446
Vancouver
Li X, Sabbatini D, Pegoraro E, Bello L, Clemens P, Guglieri M, et al. Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2446
BibTeX
@article{Li2024,
author = {Li, Xiaonan and Sabbatini, Daniele and Pegoraro, Elena and Bello, Luca and Clemens, Paula and Guglieri, Michela and van den Anker, John and Damsker, Jesse and McCall, John and Dang, Utkarsh J and Hoffman, Eric P and Jusko, William J},
title = {Assessing Pharmacogenomic loci Associated with the Pharmacokinetics of Vamorolone in Boys with Duchenne Muscular Dystrophy},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2446}
}
EUVIMED